Back to search results
NCT07222306

Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study

Enrolling by Invitation
Not specifiedAges 19–69Observational
Wayne State University
~100 participants
Updated 2025-10-29 on ClinicalTrials.gov
What's tested:1-(2-[+F]fluoroethyl)-L-tryptophan

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
[18F]FETrp K-complex
Measured over Baseline and follow-up (at least 12 weeks after baseline)
+1 more outcome measured

Conditions

PTSD
Suicidal Thoughts and Behaviors
PTSD Symptoms
Depressive Symptoms

Explore related trials

DepressionPost-Traumatic Stress DisorderSuicidal Ideation

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Eric Woodcock · PRINCIPAL_INVESTIGATOR · Wayne State University
  • Hilary Marusak, PhD · PRINCIPAL_INVESTIGATOR · Wayne State University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eligible for, and provided written informed consent to participate in, the Parent Study (NCT06381180) and to be contacted regarding 'future research studies.'
Able/willing to provide written informed consent to participate in the Neuroimaging Study.

Exclusion

Contraindications for MRI scanning include, but are not limited to: as braces, pacemaker, implanted metal (self-report MR screening form and ferromagnetic detectors) or medical conditions that prevent comfortable MRI scanning procedures, e.g., inability to lay supine for 60 minutes, claustrophobia, or body weight \> 275lbs.
Contraindications for PET \[18F\]FETrp imaging include, but are not limited to: chronic medical conditions that alter radiotracer pharmacokinetic properties, e.g, Diabetes I/II (or uncontrolled glucose levels \[\>200mg/dl non-fasting\]), abnormal BMI (\<18.5 or \> 35kg/m2), autoimmune diseases, or other chronic inflammatory conditions, or take medications (3+ days/week) that will alter radiotracer binding, e.g., glucose stabilizing medications, proton-pump inhibitors, or anti-inflammatory agents, or have medical conditions that prevent comfortable PET scanning procedures, e.g., inability to lay supine for \~75 minutes, tolerate a radial vein catheter and up to 35ml of whole blood drawn, or body weight \> 275lbs.

What this trial measures

  • [18F]FETrp K-complexBaseline and follow-up (at least 12 weeks after baseline)

    To quantify kynurenine uptake rate, a Patlak graphical analysis will be performed using the image-derived input function and the dynamic brain emission data. This method yields the unidirectional uptake rate constant, K-complex, in each brain region of interest. Outcome analyses will investigate associations with clinical symptoms and cognitive function at baseline, as longitudinal changes from baseline to follow-up with inter-group differences between dose conditions of particular interest.

  • BOLD fMRI responseBaseline and follow-up (at least 12 weeks after baseline)

    BOLD fMRI response will be isolated by contrasting activation to the contrast Go/No-Go \> Rest for the inhibitory control task, iI \> cI for the emotion regulation task, and reward \> loss for the reward task.